$104 Million is the total value of Soleus Capital Management, L.P.'s 49 reported holdings in Q4 2019. The portfolio turnover from Q3 2019 to Q4 2019 was - .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| GRFS | New | GRIFOLS S Asp adr rep b nvt | $10,548,000 | – | 452,900 | +100.0% | 10.17% | – |
| EPIX | New | ESSA PHARMA INC | $8,989,000 | – | 1,634,369 | +100.0% | 8.67% | – |
| WMGI | New | WRIGHT MED GROUP N V | $6,909,000 | – | 226,700 | +100.0% | 6.66% | – |
| ISEE | New | IVERIC BIO INC | $5,734,000 | – | 668,371 | +100.0% | 5.53% | – |
| AGN | New | ALLERGAN PLC | $5,448,000 | – | 28,500 | +100.0% | 5.26% | – |
| ADVM | New | ADVERUM BIOTECHNOLOGIES INC | $3,949,000 | – | 342,800 | +100.0% | 3.81% | – |
| DXCM | New | DEXCOM INC | $3,849,000 | – | 17,600 | +100.0% | 3.71% | – |
| AGLE | New | AEGLEA BIOTHERAPEUTICS INC | $3,500,000 | – | 458,165 | +100.0% | 3.38% | – |
| ALXN | New | ALEXION PHARMACEUTICALS INC | $3,385,000 | – | 31,300 | +100.0% | 3.26% | – |
| MSON | New | MISONIX INC | $3,323,000 | – | 178,596 | +100.0% | 3.20% | – |
| IRMD | New | IRADIMED CORP | $3,290,000 | – | 140,752 | +100.0% | 3.17% | – |
| VCEL | New | VERICEL CORP | $3,196,000 | – | 183,680 | +100.0% | 3.08% | – |
| EIGR | New | EIGER BIOPHARMACEUTICALS INC | $3,060,000 | – | 205,407 | +100.0% | 2.95% | – |
| ESTA | New | ESTABLISHMENT LABS HLDGS INC | $2,587,000 | – | 93,560 | +100.0% | 2.50% | – |
| DERM | New | DERMIRA INC | $2,495,000 | – | 164,600 | +100.0% | 2.41% | – |
| AXGN | New | AXOGEN INC | $2,280,000 | – | 127,450 | +100.0% | 2.20% | – |
| BIIB | New | BIOGEN INC | $2,225,000 | – | 7,500 | +100.0% | 2.15% | – |
| HUM | New | HUMANA INC | $2,125,000 | – | 5,800 | +100.0% | 2.05% | – |
| XENE | New | XENON PHARMACEUTICALS INC | $2,118,000 | – | 161,600 | +100.0% | 2.04% | – |
| BPMC | New | BLUEPRINT MEDICINES CORP | $2,114,000 | – | 26,400 | +100.0% | 2.04% | – |
| CNST | New | CONSTELLATION PHARMCETICLS I | $1,983,000 | – | 42,100 | +100.0% | 1.91% | – |
| FOLD | New | AMICUS THERAPEUTICS INC | $1,838,000 | – | 188,800 | +100.0% | 1.77% | – |
| HARP | New | HARPOON THERAPEUTICS INC | $1,822,000 | – | 123,200 | +100.0% | 1.76% | – |
| KDMN | New | KADMON HLDGS INC | $1,586,000 | – | 350,300 | +100.0% | 1.53% | – |
| CRSP | New | CRISPR THERAPEUTICS AGnamen akt | $1,358,000 | – | 22,300 | +100.0% | 1.31% | – |
| STE | New | STERIS PLC | $1,341,000 | – | 8,800 | +100.0% | 1.29% | – |
| STAA | New | STAAR SURGICAL CO | $1,264,000 | – | 35,940 | +100.0% | 1.22% | – |
| ZYME | New | ZYMEWORKS INC | $1,031,000 | – | 22,700 | +100.0% | 0.99% | – |
| NVRO | New | NEVRO CORP | $969,000 | – | 8,246 | +100.0% | 0.94% | – |
| ZFGN | New | ZAFGEN INC | $892,000 | – | 803,963 | +100.0% | 0.86% | – |
| ZEAL | New | ZEALAND PHARMA A Ssponsored adr | $892,000 | – | 26,882 | +100.0% | 0.86% | – |
| ICAD | New | ICAD INC | $737,000 | – | 94,900 | +100.0% | 0.71% | – |
| FLXN | New | FLEXION THERAPEUTICS INC | $722,000 | – | 34,900 | +100.0% | 0.70% | – |
| RFL | New | RAFAEL HLDGS INC | $676,000 | – | 37,925 | +100.0% | 0.65% | – |
| INSP | New | INSPIRE MED SYS INC | $668,000 | – | 9,008 | +100.0% | 0.64% | – |
| ARNA | New | ARENA PHARMACEUTICALS INC | $504,000 | – | 11,100 | +100.0% | 0.49% | – |
| TNDM | New | TANDEM DIABETES CARE INC | $453,000 | – | 7,600 | +100.0% | 0.44% | – |
| NTRA | New | NATERA INC | $437,000 | – | 13,000 | +100.0% | 0.42% | – |
| LVGO | New | LIVONGO HEALTH INC | $422,000 | – | 16,866 | +100.0% | 0.41% | – |
| ESPR | New | ESPERION THERAPEUTICS INC NE | $399,000 | – | 6,700 | +100.0% | 0.38% | – |
| GH | New | GUARDANT HEALTH INC | $382,000 | – | 4,900 | +100.0% | 0.37% | – |
| RVNC | New | REVANCE THERAPEUTICS INC | $376,000 | – | 23,200 | +100.0% | 0.36% | – |
| ARVN | New | ARVINAS INC | $357,000 | – | 8,700 | +100.0% | 0.34% | – |
| PTCT | New | PTC THERAPEUTICS INC | $326,000 | – | 6,800 | +100.0% | 0.31% | – |
| ARGX | New | ARGENX SEsponsored adr | $240,000 | – | 1,500 | +100.0% | 0.23% | – |
| SWAV | New | SHOCKWAVE MED INC | $237,000 | – | 5,400 | +100.0% | 0.23% | – |
| DRNA | New | DICERNA PHARMACEUTICALS INC | $235,000 | – | 10,700 | +100.0% | 0.23% | – |
| FATE | New | FATE THERAPEUTICS INC | $223,000 | – | 11,400 | +100.0% | 0.22% | – |
| SNDX | New | SYNDAX PHARMACEUTICALS INC | $184,000 | – | 20,980 | +100.0% | 0.18% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2020-02-14
Signatures
The EDGAR filing(s) were signed by:
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| ESSA PHARMA INC | 16 | Q3 2023 | 10.8% |
| IRADIMED CORP | 16 | Q3 2023 | 5.8% |
| XENON PHARMACEUTICALS INC | 15 | Q3 2023 | 2.9% |
| IVERIC BIO INC | 14 | Q1 2023 | 6.5% |
| SURMODICS INC | 14 | Q3 2023 | 4.7% |
| NATERA INC | 13 | Q3 2023 | 3.9% |
| DEXCOM INC | 13 | Q2 2023 | 4.2% |
| NOVOCURE LTD | 13 | Q3 2023 | 3.4% |
| CRISPR THERAPEUTICS AG | 13 | Q2 2023 | 2.6% |
| LYRA THERAPEUTICS INC | 13 | Q3 2023 | 1.0% |
View Soleus Capital Management, L.P.'s complete holdings history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2024-02-14 |
| 13F-HR | 2023-11-14 |
| 13F-HR | 2023-08-14 |
| 13F-HR | 2023-05-15 |
| 13F-HR | 2023-02-14 |
| 13F-HR | 2022-11-14 |
| 13F-HR | 2022-08-15 |
| 13F-HR | 2022-05-16 |
| 13F-HR | 2022-02-14 |
| 13F-HR | 2021-11-15 |
View Soleus Capital Management, L.P.'s complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.